araag2/HINT huggingface dataset:
Clinical trial NCT03056456 (phase 1, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: ly900014, insulin lispro (humalog)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female participants with Type 1 Diabetes Mellitus (T1DM) who are receiving
             insulin therapy via an approved insulin pump

          -  Have a screening body mass index (BMI) of greater than 18.5 to 33.0 kilograms per
             meter squared (kg/m²), inclusive

          -  Have medical and laboratory test results that are acceptable for the study

          -  Have had no episodes of severe hypoglycemia (requiring assistance in treatment by a
             second party) in the past 6 months

          -  Have venous access sufficient to allow for blood sampling

          -  Have provided written consent and are willing to follow study procedures and commit to
             the study duration

        Exclusion Criteria:

          -  Are currently participating or recently participated in a clinical trial or any other
             type of medical research judged to be incompatible with this study

          -  Had blood loss of more than 500 milliliters (mL) within the last month

          -  Have known allergies to LY900014, insulin lispro, related compounds or any components
             in the study drug formulations

          -  Have previously participated or withdrawn from this study

          -  Have or used to have health problems or medical test results that, in the opinion of
             the doctor, could make it unsafe to participate, or could interfere with understanding
             the results of the study
Clinical trial NCT03058562 (phase 1, status: completed)
Conditions: tourette syndrome, chronic motor tic disorder
ICD codes: F95.2
Drugs: abx-1431, placebo comparator, abx-1431
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Principal Inclusion Criteria:

          -  Patient is a male or female between the age of 18 and 65 years of age at the Screening
             Visit.

          -  Patient has a diagnosis of Tourette Syndrome OR chronic motor tic disorder as defined
             by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
             criteria.

          -  Patient's Yale Global Tic Severity Scale (YGTSS) total tic sub-scale (TTS) results
             must be ≥ 18 (Range 0-50) at the Screening Visit.

          -  Patients taking daily medications for symptoms of Tourette Syndrome [e.g. neuroleptics
             (e.g. aripiprazole, risperidone) or selective serotonin reuptake inhibitors (e.g.
             fluoxetine)] must be on a stable dose of medication for at least 30 days before the
             Screening Visit and must be expected to remain on a stable dose during this study.

        Principal Exclusion Criteria:

          -  Patient is taking potent cytochrome P450 3A4/5 inducers [e.g. carbamazepine,
             oxcarbazine, rifampin, St. John's Wort (Hypericum perforatum), or phenytoin]. Patient
             is taking strong P450 3A4/5 inhibitors including atazanavir, bocepravir,
             clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone,
             nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, or voriconazole.

          -  Patients with a diagnosis of any psychiatric comorbidity (obsessive compulsive
             disorder, attention deficit hyperactivity disorder) OR generalized anxiety disorder,
             depression or post-traumatic stress disorder that is unstable or requires alteration
             in therapy are excluded. Patients with a past history of psychosis or schizophrenia at
             any time are excluded. Patients with stable OCD or ADHD requiring no alteration in
             therapy may be enrolled.
Clinical trial NCT03059693 (phase 1/phase 2, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: hat1 topical cream, vehicle cream
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe atopic dermatitis as determined by Physician's Global Assessment
             (PGA > 3)

          -  Males and females, age 12 - 65 years old inclusive

        Exclusion Criteria:

          -  Is currently participating or has participated in another interventional clinical
             study at this or any other facility in the past 2 weeks.

          -  Currently or has been diagnosed or treated for cancer in the past 5 years.

          -  Requires any topical or systemic medications that could affect the course of their
             atopic dermatitis during the study period (except inhaled steroids and/or stable
             antihistamines for asthma or allergies).

          -  Has a known hypersensitivity to any corticosteroid creams.

          -  Has any active infections or has used antibiotics in the past 7 days.

          -  Has any physical attributes or skin conditions that might interfere with the clear
             visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos,
             extensive scarring, excessive hair growth or acne)

          -  Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS,
             lupus rheumatoid arthritis) which could place the subject at risk or interfere with
             the accuracy of the study results.

          -  Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5
             half-lives.

          -  Is an employee of the sponsor company or clinical testing site.

          -  Is dependent on oral medication for any skin disease/condition or could not, in the
             opinion of the Investigator tolerate the restriction of discontinuing the medicine as
             required in this study.

          -  Is currently pregnant or lactating or planning to become pregnant in the next 6 months
             (using double contraception for prevention).

          -  Has a history of keloid formation following skin injury.

          -  Is routinely taking anti-coagulant medications (i.e. Plavix, Coumadin, warfarin,
             heparin, etc.)

          -  Any other condition or factor the Investigator or their duly assigned representative
             believes may affect the ability of the subject to complete the study or the
             interpretation of the results.
Clinical trial NCT03092076 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: ticagrelor
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Age: 18 - 45 years;

          2. Sex: male and female;

          3. Ethnicity: Chinese;

          4. Good health as evidenced by the results of physical examination, vitals signs,
             electrocardiogram, and clinical laboratory test results, but there were exceptions if
             an abnormal value was considered not to be clinical significance;

          5. Written informed consent.

        Exclusion Criteria:

          1. Any conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs;

          2. Intolerance or hypersensitivity to drugs whose mechanism is similar to that of
             ticagrelor;

          3. Any history of taking medicines within half a month before enrollment;

          4. Any history of whole blood transfusion within 2 months, blood elements transfusion or
             blood donation within 1 months before enrollment;

          5. Participation in a clinical study within 3 months before enrollment;

          6. Abuse of caffeine (> 5 units/day), alcohol(> 21 units /week), smoking(> 10
             cigarettes/day);

          7. Positive serology for Hbs antigen and HIV;

          8. History of coagulation disorders.
Clinical trial NCT03102190 (phase 1, status: terminated)
Conditions: sinusitis, nasal polyps
ICD codes: J01.80, J01.90, J32.0, J32.1, J32.2, J32.3, J32.8
Drugs: verapamil hydrochloride intranasal
SMILES: COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
Reason stopped: 
    phase ii funding not available
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients presenting to the Mass Eye and Ear Sinus Center

          -  Age 18-80 yrs old

          -  Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012
             consensus criteria

          -  Post-operative with a Lund-Kennedy Poly score of <4

          -  Baseline SNOT-22 Score ≥ 30

        Exclusion Criteria:

          -  Patients with the following comorbidities:

          -  GI Hypomotility

          -  Heart Failure

          -  Liver Failure

          -  Kidney Disease

          -  Muscular Dystrophy

          -  Pregnant or Nursing Females

          -  Steroid Dependency

          -  Hypertrophic Cardiomyopathy

          -  Any Atrial or Ventricular arrhythmia (ie. Atrial fibrillation, atrial flutter, etc..)

          -  Resting Heart Rate less than 60 beats per minute

          -  Baseline Systolic Blood Pressure less than 110 mmHg

          -  Baseline Diastolic Blood Pressure less than 70 mmHg

          -  Baseline Mean Arterial Pressure Less than 60 mmHg

          -  PR interval less than 0.12 seconds

          -  Patients taking the following medications:

          -  Aspirin

          -  Beta-blockers

          -  Cimetidine(Tagamet)

          -  Clarithromycin(Biaxin)

          -  Cyclosporin

          -  Digoxin

          -  Disopyramide(Norpace)

          -  Diuretics

          -  Erythromycin

          -  Flecainide

          -  HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir)

          -  Quinidine

          -  Lithium

          -  Pioglitazone

          -  Rifampin

          -  St Johns Wort

          -  Patients with cardiac or conduction abnormality picked up by screening EKG

          -  Post-op patients with surgery within 3 months prior to enrollment.
Clinical trial NCT03122678 (phase 1, status: withdrawn)
Conditions: septic shock, shock, septic, lactic acidosis, thiamine deficiency
ICD codes: T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD, E87.2, P74.0
Drugs: thiamine, placebos
SMILES: CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    no participant enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age>18

          -  Sepsis (defined as presence of two or more SIRS criteria with documented or suspected
             infection)

          -  SIRS: Systemic Inflammatory Response Syndrome (SIRS) is the occurrence of at least two
             of the following criteria: temperature >38.0ºC or <36.0ºC, heart rate >90
             beats/minute, respiratory rate >20 breaths/minute, white blood cell count >12,000 or
             <4000.

          -  Lactate >3mmol/L at the time of consent and randomization

          -  Hypotension (systolic blood pressure <90mmHg) after a >2L fluid bolus

          -  Vasopressor dependence (defined as the continuous infusion of norepinephrine,
             dopamine, phenylephrine, vasopressin or epinephrine.)

        Exclusion Criteria:

          -  Known cirrhosis or chronic liver disease

          -  Current thiamine supplementation

          -  Clinical indication for thiamine (e.g. Alcohol abuse)

          -  Comfort measures only designation

          -  Inability to provide consent

          -  Other causes for lactate elevation (seizure, use of medications that can cause lactic
             acidosis such as metformin, linezolid and anti-retrovirals, carbon monoxide, known or
             suspected bowel or limb ischemia, cardiac arrest prior to enrollment)
Clinical trial NCT03135028 (phase 1, status: terminated)
Conditions: hematologic malignancy, acute myeloid leukemia
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A, C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: entospletinib, daunorubicin, cytarabine
SMILES: C1CN(CCO1)C1=CC=C(C=C1)N=C1NC(=CN2C=CN=C12)C1=CC2=NNC=C2C=C1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    no signal of efficacy with entospletinib
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  ENTO monotherapy (Group A): relapsed or refractory hematologic malignancies by World
             Health Organisation (WHO) criteria and who are not eligible to receive standard of
             care

          -  ENTO + cytarabine + daunorubicin (Group B): previously untreated AML by WHO criteria,
             who are deemed fit for cytarabine and daunorubicin (7+3) induction chemotherapy and
             are able to undergo up to 2 cycles of induction chemotherapy, as determined by the
             treating physician

          -  Must have been born in Japan and must not have lived outside of Japan for a period > 1
             year in the 5 years prior to Day 1 of study treatment

          -  Must be able to confirm the Japanese origin of their maternal and paternal ancestry

        Key Exclusion Criteria:

          -  Known active central nervous system or leptomeningeal leukemic involvement

          -  Ongoing liver injury, or known infection with chronic active hepatitis C virus (HCV)
             or chronic active hepatitis B virus (HBV)

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT03160001 (phase 1/phase 2, status: completed)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: placebo, niclosamide, etanercept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with RA, as defined by the American College of Rheumatology (ACR) 1987
             revised criteria or ACR/EULAR 2010,

          -  Severly Active RA by calculating either DAS28 or SDAI or CDAI.

          -  Patient selected are those who started etanercept for less than 3months and still
             active.

        Exclusion Criteria:

          -  Patients on nonsteroidal anti-inflammatory drugs (NSAID) 2 days before entry into this
             study. or methotrexate (MTX)..

          -  Patients with hypersensitivity or severe adverse effects to niclosamide .

          -  Renal impairment.

          -  Hepatic impairment.

          -  Pregnancy or a desire to become pregnant.

          -  Breast feeding.

          -  Patients with Juvenile RA [16 years old or younger].

          -  Patients using other conventional disease modifying antirheumatic drugs (DMARDs).

          -  Patients on steroid.

          -  Patients with coexistence other connective tissue diseases or hypothyroid disease.

          -  Patient with mild or inactive RA.
Clinical trial NCT03179332 (phase 1, status: completed)
Conditions: type1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: biochaperone® insulin lispro, fiasp®, novorapid®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus for more than 12 months.

          -  BMI between 18.5 and 28.5 kg/m².

          -  HbA1C level <=9.0%.

          -  Insulin treated for at least 12 months with total insulin dose <1.2U/kg/day.

        Exclusion Criteria:

          -  Type 2 Diabetes Mellitus.

          -  History of multiple and/or severe allergies to drugs or foods.

          -  Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory,
             gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of
             conditions associated with diabetes mellitus), haematological, dermatological,
             neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic
             (if female), or infectious disease, or signs of acute illness as judged by the
             Investigator.

          -  More than one episode of severe hypoglycaemia with seizure, coma or requiring
             assistance of another person during the past 6 months.

          -  Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular
             autonomic neuropathy.

          -  Females of childbearing potential, who are pregnant, breast-feeding or intend to
             become pregnant or are not using highly effective contraceptive methods.
Clinical trial NCT03192709 (phase 1/phase 2, status: unknown status)
Conditions: infertility, female
ICD codes: N97.9, N97.0, N97.1, N97.2, N97.8, Z31.81
Drugs: sildenafil vaginal suppositories
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Women with normal ovarian reserve and had at least two prior cycle with FSH <10 mIu/ml

          -  Women with history of two or three prior consecutive failed IVF/ICSI attempts using at
             least two good quality fresh or frozen-thawed embryos.

          -  Endometrial thickness on the day of hCG injection was < 9 mm in all prior IVF/ICSI
             attempts

          -  Women with normal endometrial appearance in hysteroscopy or hysterosonography or
             hysterosalpingography

        Exclusion Criteria:

          -  Women who had history of PCOS, myomectomy, Asherman's Syndrome and mullerian anomalies
Clinical trial NCT03227471 (phase 1/phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: iva, tez/iva, vx-445, matched placebo, tez, vx-561
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O, CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO
Eligibility criteria:

        Key Inclusion Criteria:

        Parts A, B, and C:

          -  Female subjects must be of non-childbearing potential.

          -  Between the ages of 18 and 55 years, inclusive.

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight >50 kg

        Parts D, E, and F:

          -  Body weight ≥35 kg.

          -  Subjects must have an eligible CFTR genotype:

               -  Parts D and F: Heterozygous for F508del and an MF mutation (F/MF)

               -  Part E: Homozygous for F508del (F/F)

          -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height.

        Key Exclusion Criteria:

        Parts A, B, and C:

          -  Any condition possibly affecting drug absorption.

          -  History of febrile illness within 14 days before the first study drug dose.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

        Parts D, E, and F:

          -  History of clinically significant cirrhosis with or without portal hypertension.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  History of solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03248713 (early phase 1, status: terminated)
Conditions: nicotine dependence
ICD codes: F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228
Drugs: mifepristone, placebo
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male smokers aged 18 to 55 years;

          -  History of smoking at least 5 cigarettes daily for the past 12 months;

          -  In good health as verified by medical history, screening examination, and -screening
             laboratory tests

        Exclusion Criteria:

          -  History of mifepristone allergy;

          -  Requirement of any form of regular psychotropic medication (antidepressants,
             antipsychotics, or anxiolytics) and recent psychiatric history (in the past 6 months);

          -  Medical illnesses including diabetes, cardiovascular, renal, endocrine, or hepatic
             disorders;

          -  Prolonged QTc interval >450 msec;

          -  History of adrenal insufficiency or a morning plasma cortisol level less than 5 mcg/dl
             at screening;

          -  Hypokalemia at screening (defined as potassium level < 3.5 mEq/L);

          -  Current use of clinically significant CYP 3A4 substrates including, simvastatin,
             lovastatin, cyclosporine, ergotamines, fentanyl, pimozide, quinidine, sirolimus,
             tacrolimus, triazolam, midazolam.

          -  use of rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's Wort.

          -  Current use of strong 3A4 inhibitors including ketoconazole, itraconazole, nefazodone,
             ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenivir, boceprevir,
             clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir,
             telaprevir, telithromycin, voriconazole.

          -  Treatment with systemic corticosteroids

          -  Current use of clinically significant CYP 3A inducers (e.g., rifampin, rifabutin);

          -  Abuse of alcohol or any other illicit or prescription drugs;

          -  Inability to tolerate cold exposure due to conditions such as peripheral -vascular
             disease or Raynaud's phenomenon;

          -  Inability to fulfill all scheduled visits and examination procedures throughout the
             study period.
Clinical trial NCT03249194 (early phase 1, status: completed)
Conditions: kidney transplant, hepatitis c
ICD codes: T86.11, T86.12, T86.13, Z94.0, T86.10, T86.19, Z48.22, B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: direct acting anti-viral therapy using epclusa or zepatier
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  No evidence of HCV infection by HCV PCR (done at the time of the initial consent)

          -  Age>60 yrs with an expected waiting time>2 years; or

          -  Age<60 yrs with any one of the following risk factors: Diabetes, coronary artery
             disease, peripheral artery disease and/or cerebrovascular disease

          -  Willingness to provide informed consent

          -  Absence of a living donor.

        Exclusion Criteria:

          -  Estimated life expectancy of less than one year based on clinical judgment of the
             investigator

          -  Prior liver or renal transplantation

          -  Pregnant women

          -  Incarcerated patients

          -  Medical or social condition which in the opinion of the investigator will interfere
             with or prevent follow-up per protocol

          -  Unable or unwilling to return for follow-up visits

        Donor Exclusion Criteria:

          -  HBV sAg positive

          -  HIV PCR or antibody positive

          -  HCV RNA negative